Short-term effects of glucagon-like peptide 1 (GLP-1) receptor agonists on fat distribution in patients with type 2 diabetes mellitus: an ultrasonography study

Acta Diabetol. 2015 Aug;52(4):727-32. doi: 10.1007/s00592-014-0710-z. Epub 2015 Jan 11.

Abstract

Aims: Glucagon-like peptide 1 receptor agonists (GLP-1 RA) induce weight loss and reduction in adipose tissue, but the effects of GLP-1 RA on the distribution of fat deposits have been poorly investigated.

Methods: In 25 patients with type 2 diabetes (16 females and 9 males, mean age 63.5 ± 8.8 years), treated with GLP-1 RA (exenatide, n. 12; liraglutide, n.13), both before and 3 months after starting treatment, an abdominal ultrasonographic scan, with Doppler of renal arteries, and echocardiography were performed. Subcutaneous fat width (peri-umbilical and sub-xiphoid), deep fat deposits (pre-aortic, peri-renal, and epicardial), and renal resistive index (RI) were evaluated.

Results: GLP-1 RA induced highly significant (p < 0.001) decrease in BMI and in fat thickness at all the assessed sites, without differences between exenatide and liraglutide treatment. A slight decrease in RI (p = 0.055) was also found. The percent changes of fat thickness was different between sites (p < 0.025), and the changes in subcutaneous deposits showed no significant correlation (p = 0.064) with those of deep fat deposits.

Conclusions: A short course of treatment with GLP-1 RA, besides weight loss, induces a redistribution of adipose tissue deposits, possibly contributing to a better cardiovascular risk profile in patients with type 2 diabetes mellitus.

MeSH terms

  • Adipose Tissue / diagnostic imaging
  • Adipose Tissue / drug effects*
  • Adipose Tissue / metabolism
  • Adult
  • Aged
  • Body Fat Distribution*
  • Cardiovascular Diseases / metabolism
  • Cardiovascular Diseases / prevention & control
  • Cardiovascular System / drug effects
  • Diabetes Mellitus, Type 2 / diagnostic imaging
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Diabetes Mellitus, Type 2 / metabolism
  • Echocardiography
  • Exenatide
  • Female
  • Follow-Up Studies
  • Glucagon-Like Peptide-1 Receptor / agonists*
  • Humans
  • Hypoglycemic Agents / pharmacology*
  • Hypoglycemic Agents / therapeutic use
  • Liraglutide / pharmacology*
  • Liraglutide / therapeutic use
  • Male
  • Middle Aged
  • Peptides / pharmacology*
  • Peptides / therapeutic use
  • Risk Factors
  • Time Factors
  • Ultrasonography
  • Venoms / pharmacology*
  • Venoms / therapeutic use

Substances

  • GLP1R protein, human
  • Glucagon-Like Peptide-1 Receptor
  • Hypoglycemic Agents
  • Peptides
  • Venoms
  • Liraglutide
  • Exenatide